A Bayesian Approach in Differential Equation Dynamic Models Incorporating Clinical Factors and Covariates.
A virologic marker, the number of HIV RNA copies or viral load, is currently used to evaluate antiretroviral (ARV) therapies in AIDS clinical trials. This marker can be used to assess the antiviral potency of therapies, but may be easily affected by clinical factors such as drug exposures and drug resistance as well as baseline characteristics during the long-term treatment evaluation process. HIV dynamic studies have significantly contributed to the understanding of HIV pathogenesis and ARV treatment strategies. Viral dynamic models can be formulated through differential equations, but there has been only limited development of statistical methodologies for estimating such models or assessing their agreement with observed data. This paper develops a mechanism-based nonlinear differential equation models for characterizing long-term viral dynamics with ARV therapy. In this model we not only incorporate clinical factors (drug exposures and susceptibility), but also baseline covariate (baseline viral load, CD4 count, weight or age) into a function of treatment efficacy. A Bayesian nonlinear mixed-effects modeling approach is investigated with application to an AIDS clinical trial study. The effects of confounding interaction of clinical factors with covariate-based models are compared using the Deviance Information Criteria (DIC), a Bayesian version of the classical deviance for model assessment, designed from complex hierarchical model settings. Relationships between baseline covariate combined with confounding clinical factors and drug efficacy are explored. In addition, we compared models incorporating each of four baseline covariates through DIC and some interesting findings are presented. Our results suggest that modeling HIV dynamics and virologic responses with consideration of time-varying clinical factors as well as baseline characteristics may play an important role in understanding HIV pathogenesis, designing new treatment strategies for long-term care of AIDS patients.
Huang
Yangxin
Y
Department of Epidemiology & Biostatistics, College of Public Health, MDC 56, University of South Florida, Tampa, FL 33612, USA.
AIDS. 1996 Dec;10 Suppl 5:S3-10
9030390
J Infect Dis. 2004 Feb 15;189(4):593-601
14767811
J Theor Biol. 1998 May 7;192(1):81-98
9628841
Nat Med. 1996 Jul;2(7):760-6
8673921
J Acquir Immune Defic Syndr. 2004 Nov 1;37(3):1358-66
15483465
Math Biosci. 1999 Aug;160(1):63-82
10465932
Proc Natl Acad Sci U S A. 1997 Oct 28;94(22):12106-11
9342370
J Pharmacokinet Biopharm. 1997 Dec;25(6):713-30
9697079
Proc Natl Acad Sci U S A. 1996 Dec 24;93(26):15323-8
8986810
J Virol. 2003 Apr;77(8):5037-8
12663814
Biometrics. 2000 Mar;56(1):293-300
10783809
Math Biosci. 2003 Aug;184(2):165-86
12832146
J Pharmacokinet Pharmacodyn. 2006 Aug;33(4):519-42
16786410
J Acquir Immune Defic Syndr. 2005 Jul 1;39(3):272-83
15980686
Stat Med. 2002 Dec 15;21(23):3655-75
12436462
Nature. 1995 Jan 12;373(6510):123-6
7816094
J Theor Biol. 2000 Apr 7;203(3):285-301
10716909
Biostatistics. 2001 Mar;2(1):13-29
12933554
Biometrics. 1999 Jun;55(2):410-8
11318194
Stat Med. 2000 Sep 15-30;19(17-18):2265-78
10960852
Nature. 1995 May 18;375(6528):193
7746311
Bull Math Biol. 2002 Jan;64(1):29-64
11868336
IEEE Trans Pattern Anal Mach Intell. 1984 Jun;6(6):721-41
22499653
Nature. 1997 May 8;387(6629):188-91
9144290
Science. 1996 Mar 15;271(5255):1582-6
8599114
Stat Med. 1998 Nov 15;17(21):2463-85
9819839
J Pharmacokinet Pharmacodyn. 2006 Aug;33(4):399-419
16583266
AIDS. 1998 Aug 20;12(12):1483-90
9727569
Proc Biol Sci. 2000 Apr 22;267(1445):835-43
10819155
AIDS. 2000 Mar 10;14(4):357-66
10770537
AIDS. 1999 Feb 25;13(3):351-7
10199225